Kinsale Capital’s strong growth, solid fundamentals, and attractive valuation present unique investment opportunities. Read here for more on KNSL stock.

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...